The Week in Review: Abcam Pays $170 Million for China-Connected Epitomics

Abcam will pay $170 million to buy Epitomics, a US mAb pharma with a China manufacturing facility; Jiangxi Boya Bio-Pharma completed a $60 million IPO on the ChiNext exchange; 3SBio will form a $20 million JV with DaVita to set up dialysis clinics in China; EntreMed reacquired the China rights to its leading cancer drug candidate; Shanghai Duyiwei Biotech will develop mAb cancer drugs with Apexigen of California; Wuhan Kindstar Diagnostics raised $20 million in a C round from western investors; Qiagen will co-market its digene HPV Test in China with KingMed Diagnostics; Wen Jiabao, China’s Premier, announced significant increases in the PRC’s investment into basic research and technology for 2012; Roche’s China revenues jumped 35% in 2011; GlaxoSmithKline is looking at a range of strategies to build its China presence; and Aslan Pharma selected PharmaNet/i3 to conduct Phase I and II clinical trials for two cancer drug candidates. More details…. Stock Symbols: (AIM: ABC) (SHA: 300294) (NSDQ: SSRX) (NYSE: DVA) (NSDQ: ENMD) (NSDQ: QGEN) (VS: ROG) (NYSE: GSK) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});